Gsk3B ([Glycogen Synthase Kinase] 3 Beta) is an important component in the neurobiology of neurodegenerative [diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/[diseases[/diseases. This page provides detailed information about its structure, function, and role in disease processes.
[GSK3B[/proteins/[gsk3b[/proteins/[gsk3b[/proteins/[gsk3b[/proteins/[gsk3b--TEMP--/proteins)--FIX-- ([Glycogen Synthase Kinase] 3 Beta) is a constitutively active serine/threonine protein kinase that occupies a central position in [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX-- pathogenesis through its dual involvement in tau] hyperphosphorylation and [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- production. Originally discovered in 1980 as a regulator of glycogen metabolism, [GSK3B[/proteins/[gsk3b[/proteins/[gsk3b[/proteins/[gsk3b[/proteins/[gsk3b--TEMP--/proteins)--FIX-- has since been recognized as a multifunctional kinase involved in over 100 substrates spanning Wnt signaling, insulin signaling, cell cycle regulation, [apoptosis[/entities/[apoptosis[/entities/[apoptosis[/entities/[apoptosis[/entities/[apoptosis--TEMP--/entities)--FIX--, and [neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation[/mechanisms/[neuroinflammation--TEMP--/mechanisms)--FIX--. In the central nervous system, [GSK3B[/proteins/[gsk3b[/proteins/[gsk3b[/proteins/[gsk3b[/proteins/[gsk3b--TEMP--/proteins)--FIX-- is the predominant isoform and is highly expressed in [neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons[/entities/[neurons--TEMP--/entities)--FIX--, particularly in the [hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus[/brain-regions/[hippocampus--TEMP--/brain-regions)--FIX-- and [cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex[/brain-regions/[cortex--TEMP--/brain-regions)--FIX--, regions most vulnerable to [Alzheimer]'s pathology (Beurel et al., 2015).
[GSK3B[/proteins/[gsk3b[/proteins/[gsk3b[/proteins/[gsk3b[/proteins/[gsk3b--TEMP--/proteins)--FIX-- has been called a "master kinase" in AD because it links the two hallmark pathologies — amyloid plaques and neurofibrillary tangles — through feed-forward loops: [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- oligomers activate [GSK3B[/genes/[gsk3b[/genes/[gsk3b[/genes/[gsk3b[/genes/[gsk3b--TEMP--/genes)--FIX--, which then hyperphosphorylates tau and promotes further amyloid production. This central position makes [GSK3B[/genes/[gsk3b[/genes/[gsk3b[/genes/[gsk3b[/genes/[gsk3b--TEMP--/genes)--FIX-- one of the most actively pursued therapeutic targets in AD drug development, though challenges related to its broad substrate specificity and essential physiological functions have slowed clinical progress (Hooper et al., 2008).
[GSK3B[/genes/[gsk3b[/genes/[gsk3b[/genes/[gsk3b[/genes/[gsk3b--TEMP--/genes)--FIX-- has a bilobal kinase fold with distinct regulatory features:
Unlike most kinases, [GSK3B[/genes/[gsk3b[/genes/[gsk3b[/genes/[gsk3b[/genes/[gsk3b--TEMP--/genes)--FIX-- is constitutively active and regulated primarily through inhibition:
[GSK3B[/genes/[gsk3b[/genes/[gsk3b[/genes/[gsk3b[/genes/[gsk3b--TEMP--/genes)--FIX-- is the principal kinase responsible for disease-relevant tau hyperphosphorylation] in AD. It phosphorylates tau] at over 40 sites, including many that are hyperphosphorylated in AD brain, most notably Thr181, Ser199, Ser202, Thr205, Thr231, Ser235, Ser396, and Ser404 (Hernandez et al., 2013).
A landmark 2024 study demonstrated that GSK3B phosphorylation directly catalyzes the aggregation of full-length tau into [Alzheimer's disease[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers[/diseases/[alzheimers--TEMP--/diseases)--FIX---like paired helical filaments (PHFs). Using cryo-electron microscopy, the [researchers[/[researchers[/[researchers[/[researchers[/[researchers[/[researchers[/[researchers[/[researchers[/researchers showed that phosphorylation by GSK3B — but not by CDK2, DYRK1A, CK1, or MARK — promotes tau phase separation into gel-like condensates and subsequent fibrillization into structures with folds comparable to those isolated from AD brains. This was the first demonstration that a single kinase could reproduce the disease-specific tau fold in vitro (Haj-Yahya et al., 2024).
A 2025 review highlighted that age-dependent dysregulation of GSK3B is a key driver of the transition from normal aging to AD. Reduced insulin/IGF-1 signaling with aging leads to decreased Akt-mediated Ser9 phosphorylation, progressively disinhibiting GSK3B activity and accelerating tau pathology]. This provides a mechanistic link between metabolic aging and tau-driven neurodegeneration ([GSK-3β[/entities/[gsk3-beta[/entities/[gsk3-beta[/entities/[gsk3-beta[/entities/[gsk3-beta--TEMP--/entities)--FIX-- dysregulation review, 2025https://doi.org/10.1016/j.biocel.2025.106719)).
GSK3B influences [amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta[/entities/[amyloid-beta--TEMP--/entities)--FIX-- production through multiple mechanisms:
GSK3B is a key regulator of innate immune responses in the brain:
GSK3B negatively regulates synaptic plasticity and memory:
| Compound | Type | Status | Key Findings |
|---|---|---|---|
| Lithium | Non-selective GSK3 inhibitor (ATP-competitive) | Approved (bipolar disorder); epidemiological AD studies | Long-term lithium use associated with reduced dementia risk; pilot trials showed reduced tau phosphorylation biomarkers |
| Tideglusib | Irreversible, non-ATP-competitive GSK3 inhibitor (TDZD class) | Phase II completed (AD) | ARGO trial: no significant cognitive benefit at primary endpoints, but possible biomarker effects; dose-limiting hepatotoxicity at higher doses |
| 9-ING-41 (elraglusib) | ATP-competitive GSK3 inhibitor | Phase I/II (oncology); preclinical (neurodegeneration) | Potent brain-penetrant GSK3 inhibitor with promising safety profile |
GSK3B phosphorylates [alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein[/proteins/[alpha-synuclein--TEMP--/proteins)--FIX--] at Ser129, the predominant phosphorylation site found in Lewy bodies. GSK3B activation also contributes to [dopaminergic neurodegeneration[/mechanisms/[dopaminergic-neurodegeneration[/mechanisms/[dopaminergic-neurodegeneration[/mechanisms/[dopaminergic-neurodegeneration[/mechanisms/[dopaminergic-neurodegeneration--TEMP--/mechanisms)--FIX-- through impaired [mitophagy[/mechanisms/[mitophagy[/mechanisms/[mitophagy[/mechanisms/[mitophagy[/mechanisms/[mitophagy--TEMP--/mechanisms)--FIX-- signaling.
Mutant [huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- protein activates GSK3B, which in turn phosphorylates [huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin[/proteins/[huntingtin--TEMP--/proteins)--FIX-- at Ser421, modulating its toxicity. GSK3 inhibition reduces striatal neurodegeneration in HD mouse models.
GSK3B is implicated in [MAPT[/genes/[mapt[/genes/[mapt[/genes/[mapt[/genes/[mapt--TEMP--/genes)--FIX---mutation FTD through tau hyperphosphorylation, and in [GRN[/genes/[grn[/genes/[grn[/genes/[grn[/genes/[grn--TEMP--/genes)--FIX---mutation FTD through regulation of [TDP-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43[/entities/[tdp-43--TEMP--/entities)--FIX-- phosphorylation.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
The study of Gsk3B ([Glycogen Synthase Kinase] 3 Beta) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Glycogen Synthase Kinase 3 beta (GSK-3β) is a serine/threonine kinase that plays a central role in neuronal function and dysfunction. As a key regulator of tau phosphorylation, glycogen metabolism, and synaptic plasticity, GSK-3β has emerged as a critical therapeutic target in neurodegenerative disease research. Increased GSK-3β activity has been implicated in Alzheimer's disease pathogenesis through promoting tau hyperphosphorylation, amyloid-β production, and neuroinflammation. Inhibitors of GSK-3β have shown promise in preclinical models, though challenges remain in achieving brain penetration and selectivity. The development of selective GSK-3β modulators and understanding of its cell-type specific functions continue to be active areas of investigation. Targeting GSK-3β-mediated pathways represents a promising strategy for developing disease-modifying treatments for Alzheimer's disease and related tauopathies.
| Domain | Position | Function |
|---|---|---|
| N-terminal | 1-100 | Binding |
| Central | 101-300 | Catalytic |
| C-terminal | 301-400 | Localization |